

IN THE CLAIMS

Please cancel claims 3, 8, 10, 12, 14-15 and 20, without prejudice or disclaimer of any subject matter herein.

Rewrite claims 1 and 2 as follows:

1 (Amended). A chimaeric polypeptide comprising:

- (a) a scFv having specific binding affinity for a eucaryotic target cell surface component;
- (b) an effector portion comprising at least one copy of an immunogenic peptide having the sequence KYICNSSCM or GILGFVFTL; and optionally
- (c) a signal derived from the translocation domain of HIV tat protein directing the immunogenic peptide to a particular cellular component, whereby binding of the chimaeric polypeptide to the cell surface component induces internalisation of at least the effector portion to allow the at least one copy of the immunogenic peptide to be presented by MHC molecules on the target cell surface.

2. A chimaeric polypeptide comprising: a scFv, from a first source, having specific binding affinity for a eukaryotic target cell surface component; an effector portion, from a second source, comprising at least one copy of an immunogenic peptide having the sequence KYICNSSCM or GILGFVFTL, and a translocation

portion derived from the translocation domain of HIV tat protein,
the translocation portion being adjacent to the effector portion;
whereby binding of the polypeptide to the cell surface component
induces internalization of at least the effector and
translocation portions so as to allow the effector portion to
enter the cytosol of the target cell and hence all the peptide to
induce cell lysis.

Rewrite claim 9 as follows:

9 (Amended). A polypeptide according to claim 1 or 2
wherein the effector portion comprises a number of repeats of the
same peptide.

Rewrite claims 21 and 23 as follows:

21 (Amended). A method of stimulating cell lysis of a human
or animal subject, comprising administering to the subject an
effective amount of a polypeptide in accordance with claim 1 or
2.

23 (Amended). A method according to claim 22, wherein
administering the polypeptide causes the target cell to present a
CTL epitope which is foreign to the target cell.

REMARKS

In accordance with the above-amendments, the specification
has been amended to identify the sequences in the specification
by SEQ ID NO., as requested by the Examiner. This is believed to